Credit: Fresenius Kabi. Conexxence and Bomyntra were approved by the FDA in March 2025. The interchangeability designation allows the biosimilars to be substituted for the reference product at the ...
In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...
This was corrected on 09/19/2025 at 9:35 AM. The revised post corrects the company name to Organon in the headline.
LOS ANGELES (Reuters) - A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company ...
Bosaya and Aukelso are FDA-approved biosimilars for managing bone health in cancer patients, offering cost-effective alternatives to Prolia and Xgeva. Bosaya targets bone loss prevention in prostate ...
In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Organon & Co. stands eleventh among them. Organon & Co. (NYSE:OGN), a global healthcare company focused on women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback